Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897748008> ?p ?o ?g. }
- W2897748008 endingPage "16" @default.
- W2897748008 startingPage "3" @default.
- W2897748008 abstract "Abstract PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of VEGF production and cell proliferation by PTC299 is linked to a decrease in uridine nucleotides by targeting dihydroorotate dehydrogenase (DHODH), a rate-limiting enzyme for de novo pyrimidine nucleotide synthesis. Unlike previously reported DHODH inhibitors that were identified using in vitro enzyme assays, PTC299 is a more potent inhibitor of DHODH in isolated mitochondria suggesting that mitochondrial membrane lipid engagement in the DHODH conformation in situ is required for its optimal activity. PTC299 has broad and potent activity against hematologic cancer cells in preclinical models, reflecting a reduced pyrimidine nucleotide salvage pathway in leukemia cells. Archived serum samples from patients treated with PTC299 demonstrated increased levels of dihydroorotate, the substrate of DHODH, indicating target engagement in patients. PTC299 has advantages over previously reported DHODH inhibitors, including greater potency, good oral bioavailability, and lack of off-target kinase inhibition and myelosuppression, and thus may be useful for the targeted treatment of hematologic malignancies." @default.
- W2897748008 created "2018-10-26" @default.
- W2897748008 creator A5005987573 @default.
- W2897748008 creator A5007632399 @default.
- W2897748008 creator A5011563257 @default.
- W2897748008 creator A5013562958 @default.
- W2897748008 creator A5019285587 @default.
- W2897748008 creator A5021647682 @default.
- W2897748008 creator A5026852635 @default.
- W2897748008 creator A5027381296 @default.
- W2897748008 creator A5027918265 @default.
- W2897748008 creator A5028627010 @default.
- W2897748008 creator A5032141712 @default.
- W2897748008 creator A5032509378 @default.
- W2897748008 creator A5044239371 @default.
- W2897748008 creator A5050034826 @default.
- W2897748008 creator A5056763549 @default.
- W2897748008 creator A5060007368 @default.
- W2897748008 creator A5063193141 @default.
- W2897748008 creator A5063241262 @default.
- W2897748008 creator A5063440637 @default.
- W2897748008 creator A5070670286 @default.
- W2897748008 creator A5071707596 @default.
- W2897748008 creator A5076539329 @default.
- W2897748008 creator A5076684353 @default.
- W2897748008 creator A5087253726 @default.
- W2897748008 creator A5087545685 @default.
- W2897748008 creator A5087990265 @default.
- W2897748008 creator A5088185086 @default.
- W2897748008 creator A5088274566 @default.
- W2897748008 creator A5089722456 @default.
- W2897748008 date "2019-01-01" @default.
- W2897748008 modified "2023-10-12" @default.
- W2897748008 title "Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties" @default.
- W2897748008 cites W1511496461 @default.
- W2897748008 cites W1694770116 @default.
- W2897748008 cites W1756949381 @default.
- W2897748008 cites W1773171738 @default.
- W2897748008 cites W1868360480 @default.
- W2897748008 cites W1986602125 @default.
- W2897748008 cites W1995948477 @default.
- W2897748008 cites W1996774325 @default.
- W2897748008 cites W2014063489 @default.
- W2897748008 cites W2024074032 @default.
- W2897748008 cites W2032190412 @default.
- W2897748008 cites W2043398720 @default.
- W2897748008 cites W2057650061 @default.
- W2897748008 cites W2064922889 @default.
- W2897748008 cites W2073120856 @default.
- W2897748008 cites W2078959398 @default.
- W2897748008 cites W2091765441 @default.
- W2897748008 cites W2092911406 @default.
- W2897748008 cites W2100778027 @default.
- W2897748008 cites W2115921217 @default.
- W2897748008 cites W2116374674 @default.
- W2897748008 cites W2127026287 @default.
- W2897748008 cites W2133708837 @default.
- W2897748008 cites W2257562765 @default.
- W2897748008 cites W2319133123 @default.
- W2897748008 cites W2326773753 @default.
- W2897748008 cites W2334877168 @default.
- W2897748008 cites W2343661991 @default.
- W2897748008 cites W2345381093 @default.
- W2897748008 cites W2408317479 @default.
- W2897748008 cites W2416794461 @default.
- W2897748008 cites W2420992238 @default.
- W2897748008 cites W2472864907 @default.
- W2897748008 cites W2520159331 @default.
- W2897748008 cites W2526797893 @default.
- W2897748008 cites W2565096602 @default.
- W2897748008 cites W2565972943 @default.
- W2897748008 cites W2586749844 @default.
- W2897748008 cites W2588063327 @default.
- W2897748008 cites W2590621600 @default.
- W2897748008 cites W2592487518 @default.
- W2897748008 cites W2706229700 @default.
- W2897748008 cites W2756294165 @default.
- W2897748008 cites W2782920688 @default.
- W2897748008 cites W2790599519 @default.
- W2897748008 cites W2793033519 @default.
- W2897748008 cites W2796148399 @default.
- W2897748008 cites W2806824289 @default.
- W2897748008 cites W3050161759 @default.
- W2897748008 cites W55510815 @default.
- W2897748008 cites W915605497 @default.
- W2897748008 cites W1490528897 @default.
- W2897748008 cites W1605584133 @default.
- W2897748008 doi "https://doi.org/10.1158/1535-7163.mct-18-0863" @default.
- W2897748008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6318026" @default.
- W2897748008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30352802" @default.
- W2897748008 hasPublicationYear "2019" @default.
- W2897748008 type Work @default.
- W2897748008 sameAs 2897748008 @default.
- W2897748008 citedByCount "59" @default.
- W2897748008 countsByYear W28977480082019 @default.
- W2897748008 countsByYear W28977480082020 @default.
- W2897748008 countsByYear W28977480082021 @default.
- W2897748008 countsByYear W28977480082022 @default.